Client: Peter McCallum Cancer Centre

Context: Theranostic treatment for prostate cancer involves targeting prostate specific membrane antigen (PSMA) on prostate cancer cells – first with a radioactive molecule to reveal the cancer’s spread via a PET scan and then a similar radioactive molecule that kills cancer cells. Peter Mac has pioneered research globally in this field. LuCAB is a prospective phase I/II trial to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of Cabazitaxel in combination with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).

This infographic, supported by an animated Powerpoint presentation, provides a snapshot understanding of the trial’s context, reasoning and protocol. It is aimed at both the medical research community and potential patients.


LUCAB Clinical trial scientific poster for ASCO symposium
LUCAB clinical tria infographic